What this is
- How it works
- How it works isn't classified yet
- Tested for
- Macular Edema Secondary to Inflammation (2 trials)
- Main trialPhase 3
- “A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)”In the company’s words, NCT06996080 on ClinicalTrials.gov
- Other names
- tabirafusp alfa
Other drugs for Macular Edema Secondary to Inflammation
- MK-8748Merck & Co. · Phase 3
- KIO-104Kiora Pharmaceuticals, Inc. · Phase 2
- BI 1815368Boehringer Ingelheim · Phase 2
- DF-003Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Phase 1
- MS-553MingSight Pharmaceuticals, Inc · Phase 1
Coming up2
- Feb 2027Phase 3 trial completes · ClinicalTrials.gov
- Apr 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Feb 2027 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | |
| Phase 3Recruiting | Apr 2027 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026